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INTRODUCTION

76
There is an estimated global burden of 290 million cases of chronic hepatitis B virus 77 (HBV) infection (1), the majority of which are undiagnosed and untreated (2).
78
Prevalence of HBV exposure and infection can be extremely high in some settings in Fig 1) . We used the search terms "HBV antibody", "anti-HBc", "HB core 146 antibody", "HBV exposure" or "HBV prevalence" AND "Africa" or [Name of specific 147 country], using the list of countries on the United Nations (UN) geoscheme for Africa 148 (https://unstats.un.org/unsd/methodology/m49/).
150
Inclusion criteria were as follows: 
159
We recorded total anti-HBc prevalence (i.e. proportion of population exposed to HBV, 160 irrespective of chronic infection status, termed 'total exposure') and also calculated the 161 proportion of the population with cleared infection (i.e. anti-HBc prevalence minus 162 HBsAg prevalence, termed 'exposed and cleared'). For studies reporting prevalence 163 data from ≥2 cohorts (e.g. HIV-positive and HIV-negative populations), we recorded 164 these as a single publication but ≥2 distinct data points. Studies in a language other 165 than English were translated using Google Translate (https://translate.google.com/).
166
We considered Uganda as an exemplar setting where HBsAg seroprevalence in adults 
173
Ethics approval was not required for this study, as we analysed data that are already 174 available in the public domain.
176
Statistical analysis of metadata 177
The UN geoscheme classifies Africa into Central, Eastern, Northern, Southern and 178 Western regions; this is a standard approach for sub-dividing macro-geographical 179 areas for statistical analysis. For the regional analysis, each study was assigned equal 180 weighting when analyzing the data, regardless of the study size. We analysed 181 8 prevalence data for anti-HBc and HBsAg using Graphpad Prism v7 . 0. For non-182 parametric data, we sought significant differences between data sets using Mann-183 Whitney U tests, and for multiple comparisons we used 1-way ANOVA. We used linear 184 regression to derive lines of best fit, 95% confidence intervals and to interpolate HBsAg 185 prevalence from anti-HBc prevalence. We generated maps to illustrate the location of 186 the HBV cohorts and seroprevalence of relevant markers using R (Source code will be 187 made available on acceptance at the following link:
188 https://github.com/ArmandBester/Serology_of_HBV_in_Africa).
190
Modelling the impact of adult vaccination vs. 'test and treat'
191
In this study we adapted a published dynamic model and Bayesian Markov Chain
192
Monte Carlo approach that we previously developed to fit the seroepidemiology of a 
224
The distribution of these cohorts and the prevalence of HBV serological markers is prevalence rates of infection than other regions ( Fig 2B and Fig 3A,B) . In contrast,
237
Western Africa has the highest population exposure and correspondingly highest rates 238 of HBsAg positivity (Fig 2E, Fig 3) . HBsAg prevalence differs significantly between 239 regions (for Northern Africa compared to Western and Southern Africa, p=0.0002 and 240 p=0.04 respectively, Fig 3B) ; and cannot be explained only by lower population 241 exposure rates: although anti-HBc prevalence is somewhat lower in Northern than
242
Western Africa (p=0.001), there is no difference in anti-HBc prevalence between
243
Southern and Northern Africa (p=0.99). Indeed, the predicted HBsAg prevalence was 244 approximately 50% lower in Northern than Southern Africa for any given anti-HBc 245 prevalence ( Fig 2B, 2D ; Suppl Table 3 ). 
257
In three studies that assessed both HIV-positive and HIV-negative cohorts, HBsAg 258 prevalence was higher among HIV-positive subjects (mean 2.23-fold) (22-24). Anti-
259
HBc prevalence was also higher in HIV-positive cohorts than in HIV-negative cohorts 260 for 2/3 studies (22, 24) . In a third study of highly exposed cohorts in South Africa, anti-
11
HBc prevalence was similar irrespective of HIV status, suggesting the increased
262
HBsAg prevalence in the HIV-positive cohort was the result of reduced clearance rates 263 relative to the HIV-negative cohort (23).
265
Impact of catch-up vaccination of adolescents and adults 266
We did not identify any published evidence or specific recommendations for catch-up Suppl Table 4 ).
272
Based on combining the mean prevalence values from Uganda cohorts to provide a 273 broad overview, 54% of adults across this country have been exposed (among these, 
298
Impact of 'test and treat' in highly endemic settings 299
We also modelled the impact of 'test and treat', based on the premise that the whole 300 population is screened, projecting that this strategy has the fastest reduction in HBV 
336
there is evidence of region-specific differences in exposure and transmission.
338
In order to make progress towards HBV elimination goals, we therefore suggest that 
351
and additional scrutiny will be required for drug resistance (33).
353
The 
360
Relationship between exposure and active HBV infection in Africa
361
Our seroepidemiology review highlighted considerable regional differences in the 
385
Relationship between HBV and HIV 386
There was no evidence from our dataset that HIV+ individuals were more likely to be 387 either HBV infected or exposed, in keeping with previous reports (36 
405
which is rarely detected due to lack of availability and high cost of HBV DNA testing.
406
However, individuals with occult HBV would still generate anti-HBc; thus while we may 407 be underestimating the prevalence of active infection, these subjects are still included 408 within our exposed population.
410
We did not include data for anti-HBs prevalence (immunised population) as a limited 411 number of papers report the prevalence of anti-HBs together with anti-HBc and HBsAg 412 data. The most common reason for study exclusion form the literature review was no 413 anti-HBc prevalence reported ( Suppl Fig 1) . Making the inclusion criteria more 414 stringent would have limited the findings from the study.
416
We included papers published after the EPI introduction of HBV vaccine in 1995, in 417 order to make our study applicable to current-day vaccinated populations, although in 418 practice, roll-out of the vaccine was patchy and adopted at a variable rate over the 419 decade that followed. There are limited data for many regions describing the 420 prevalence of three-dose vaccine coverage. Based on the age of adults represented 421 in most of our cohorts, we can assume the majority of subjects in the study were 422 unlikely to have been vaccinated at birth. Future sero-surveys will provide more 423 insights into the impact of routine infant HBV vaccination. An assessment of vaccine- 
458
We advocate significant investment in capacity building for improving HBV diagnosis 
463
Table 1: Factors that may contribute to regional differences in prevalence of anti-
464
HBc and HBsAg across Africa
465
Factor Rationale for contribution to regional differences in HBV seroepidemiology Circulating HBV viral genotype Predominant genotype varies by region with genotype-A common in Southern Africa, genotype-D in the North and genotype-E in the West (39).
Host ethnicity and genetics
HLA-type and T-cell repertoire have been linked to the ability to control the infection (40-42).
Transmission differences
Subtle differences in the transmission patterns (vertical vs horizontal) of the HBV genotypes have been documented. Transmission route is fundamentally linked to age at exposure (43).
Age at exposure
The probability of developing chronic HBV after exposure is strongly associated with age (44). Populations with a younger age at exposure are therefore likely to have a higher HBsAg prevalence relative to the anti-HBc prevalence (Fig 5A) .
Co-infection within population
Risk factors for acquisition of blood-borne viruses overlap between HIV, HBV and HCV. Egypt and the Nile Delta have some of the highest reported prevalences of HCV globally. Co-infection of HBV and HCV has been linked to spontaneous clearance of HCV although evidence of the impact on HBV remains scarce (45, 46).
Political instability
Central Africa includes several regions disrupted by recent conflict and resulting population migration, with powerful influence on increases in interpersonal violence and sexual assault, reduced access to barrier contraception, inadequate screening of blood products, and reduced access to healthcare, all of which can increase exposure rates in the adult population.
Traditional cultural practices
Exposure to blood-borne viruses is influenced by traditional healing practices, scarification, piercing, tattooing and non-sterile surgical practice (e.g. circumcision).
Uptake of HBV vaccination in the region
Countries with earlier uptake of the HBV vaccine are likely to have lower anti-HBc and HBsAg prevalence than countries that implemented the vaccine later. Prevalence of vaccine escape mutants may contribute, although data for Africa are scarce (33).
Potential role of insect vector
Biting insects capable of mechanical transmission of HBV may be prevalent in some regions, although there is a lack of firm evidence base for HBV transmission (47). 
530
In adults, assuming that different populations are exposed at the same rate and the 531 risk of chronic infection is constant (estimated to be 5% in healthy adults as shown in vaccination on incidence is therefore related to S, with reduced impact in highly 537 exposed populations. In a test and treat scenario, with 50% of cases identified and 538 treated, incidence is consistently reduced, regardless of S. 
555
Western and Central Africa with a given anti-HBc prevalence. Data to inform the 556 analysis were derived from a systematic literature review (full metadata on-line)(21).
557
Linear regression analysis data for the African regions was simulated to predict HBsAg 558 prevalence with a given anti-HBc prevalence ranging from 5-60% and increasing in 559 increments of 5%. Values plotted in Suppl. Fig 3. 
561
Suppl. 
577
Western and Central regions of Africa with a given total anti-HBc prevalence 578 (reflecting exposure). Linear regression analysis data for each region was simulated 579 to predict HBsAg prevalence with a given anti-HBc prevalence ranging from 5-60% 580 and increasing in increments of 5%. Plotted from values given in Suppl. 
